Literature DB >> 12835121

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Masato Asanuma1, Ikuko Miyazaki, Norio Ogawa.   

Abstract

Dopamine (DA)- or L-dihydroxyphenylalanine-(L-DOPA-) induced neurotoxicity is thought to be involved not only in adverse reactions induced by long-term L-DOPA therapy but also in the pathogenesis of Parkinson's disease. Numerous in vitro and in vivo studies concerning DA- or L-DOPA-induced neurotoxicity have been reported in recent decades. The reactive oxygen or nitrogen species generated in the enzymatical oxidation or auto-oxidation of an excess amount of DA induce neuronal damage and/or apoptotic or non-apoptotic cell death; the DA-induced damage is prevented by various intrinsic and extrinsic antioxidants. DA and its metabolites containing two hydroxyl residues exert cytotoxicity in dopaminergic neuronal cells mainly due to the generation of highly reactive DA and DOPA quinones which are dopaminergic neuron-specific cytotoxic molecules. DA and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. For example, the formation of DA quinone-alpha-synuclein consequently increases cytotoxic protofibrils and the covalent modification of tyrosine hydroxylase by DA quinones. The melanin-synthetic enzyme tyrosinase in the brain may rapidly oxidize excess amounts of cytosolic DA and L-DOPA, thereby preventing slowly progressive cell damage by auto-oxidation of DA, thus maintainng DA levels. Since tyrosinase also possesses catecholamine-synthesizing activity in the absence of tyrosine hydroxylase (TH), the double-edged synthesizing and oxidizing functions of tyrosinase in the dopaminergic system suggest its potential for application in the synthesis of DA, instead of TH in the degeneration of dopaminergic neurons, and in the normalization of abnormal DA turnover in the long-term L-DOPA-treated Parkinson's disease patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835121     DOI: 10.1007/bf03033137

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  112 in total

1.  Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.

Authors:  M Gómez-Vargas; S Nishibayashi-Asanuma; M Asanuma; Y Kondo; E Iwata; N Ogawa
Journal:  Brain Res       Date:  1998-04-20       Impact factor: 3.252

2.  Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.

Authors:  B Ferger; P Teismann; C D Earl; K Kuschinsky; W H Oertel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-09       Impact factor: 3.000

3.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

4.  Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.

Authors:  K L Double; L Zecca; P Costi; M Mauer; C Griesinger; S Ito; D Ben-Shachar; G Bringmann; R G Fariello; P Riederer; M Gerlach
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

5.  The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.

Authors:  J Smythies
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

6.  Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.

Authors:  J P Spencer; P Jenner; S E Daniel; A J Lees; D C Marsden; B Halliwell
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

7.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

Authors:  B Pardo; M A Mena; M J Casarejos; C L Paíno; J G De Yébenes
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

8.  Cysteinyldopamine is not incorporated into neuromelanin.

Authors:  K Wakamatsu; S Ito; T Nagatsu
Journal:  Neurosci Lett       Date:  1991-09-30       Impact factor: 3.046

9.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

10.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.

Authors:  N Ogawa; K Tanaka; M Asanuma; M Kawai; T Masumizu; M Kohno; A Mori
Journal:  Brain Res       Date:  1994-09-19       Impact factor: 3.252

View more
  114 in total

Review 1.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

Review 2.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

3.  A neuroinductive biomaterial based on dopamine.

Authors:  Jin Gao; Yu Mi Kim; Herna Coe; Blaine Zern; Barbara Sheppard; Yadong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 4.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

5.  Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson's disease.

Authors:  Nadella Kumudini; Addepally Uma; Shaik Mohammad Naushad; Rukmini Mridula; Rupam Borgohain; Vijay Kumar Kutala
Journal:  Neurol Sci       Date:  2014-01-04       Impact factor: 3.307

Review 6.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

Review 7.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

8.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

9.  Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.

Authors:  Eun-Joo Shin; Seung Woo Shin; Thuy-Ty Lan Nguyen; Dae Hun Park; Myung-Bok Wie; Choon-Gon Jang; Seung-Yeol Nah; Byung Wook Yang; Sung Kwon Ko; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2014-01-16       Impact factor: 5.590

Review 10.  Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease.

Authors:  Takafumi Hasegawa
Journal:  Int J Mol Sci       Date:  2010-03-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.